Two Nodes, Grade 2, 4.9 Centimeters: Reading monarchE's Fine Print
She meets monarchE's node count but not its grade or its size threshold — sitting a few millimeters and one histologic grade outside the trial's own entry criteria. Whether abemaciclib's benefit extends to a patient who is almost, but not quite, the trial population is a genuine eligibility question, not a formality.
Angela P., a 49-year-old single mother raising two teenagers on her own, scheduled her diagnostic workup around her daughter's volleyball tournament and her son's driver's test — the kind of logistics that don't stop mattering just because a biopsy came back malignant. Her tumor measured 4.9cm at surgical pathology, with two of sixteen nodes positive — two short of the four-node threshold that would have settled her risk tier outright — and a grade 2 histology, findings that put her right at the edge of monarchE's own eligibility criteria rather than cleanly inside or outside it.
monarchE enrolled its patients in two separate cohorts. Cohort 1 took four or more positive axillary nodes on their own, or one to three positive nodes plus grade 3 histology or a tumor 5cm or larger. Cohort 2 took patients who could not qualify for Cohort 1 — one to three positive nodes with a Ki-67 of 20% or higher and nothing else. Angela lands in Cohort 2 and nowhere else: her 4.9cm tumor is one millimeter under the 5cm cutoff, her histology is grade 2, and it is her Ki-67 of 22% doing all the work. That placement matters more than it first appears, because Cohort 1 carried roughly 91% of the trial's 5,637 patients and the significant invasive disease-free survival difference was attributed primarily to Cohort 1; her cohort is the small, less decisive slice of the result. The larger problem is that the criterion she qualifies under no longer exists where it counts. Abemaciclib's original October 2021 adjuvant approval did require a Ki-67 of 20% or higher, but in March 2023 the FDA removed the Ki-67 testing requirement entirely, and the current indication defines high risk by nodal status, tumor size, and grade alone — four or more positive nodes, or one to three positive nodes with grade 3 histology or a tumor of at least 50mm. Angela meets none of those. Her Ki-67 of 22% would have made her label-eligible under the 2021 wording and makes her trial-eligible under Cohort 2 today; under the label actually in force it is no longer a selection criterion at all, which means the number the team is preparing to re-test is one the FDA has already stopped using.
Multidisciplinary tumor board, eligibility review
Her Ki-67 of 22% puts her inside monarchE's Cohort 2 on the trial's own terms — 1 to 3 positive nodes with a high Ki-67 and no other qualifying feature. That is a real enrolled population with a real result behind it, and I would start two years of abemaciclib alongside endocrine therapy on that basis.
Before we treat 22% as the number that decides this, I have to say plainly that it is no longer the number that decides anything. The FDA removed Ki-67 from abemaciclib's adjuvant selection criteria in March 2023 — the indication now runs on nodes, size, and grade, and by those she does not qualify. I spend my days defending the reproducibility of this assay and I will still tell you it was dropped for a defensible reason: inter-laboratory variability on Ki-67 immunohistochemistry is real enough that a 22% here could read 18% across town, which is precisely the fragility a regulator does not want carrying an eligibility decision.
Then we are arguing about two different things, because the trial population and the labeled population have come apart. Cohort 2 was enrolled, treated, and reported; her being in it is a fact about the evidence, not about the label. What I take from your point is narrower than you intend it — not that she is ineligible, but that repeating the stain answers a question nobody is being asked anymore.
A repeat stain is the one thing I would not do, and I want to be direct about why, because it is the intuitive move: a second Ki-67 cannot make her label-eligible if it comes back at 30%, and cannot make her trial-ineligible in any way that matters if it comes back at 18%. It resolves nothing and costs her weeks. The disputed fact here is not the assay, it is whether we treat a Cohort 2 result as sufficient grounds for off-label use.
Which is a decision that has to be made on its own merits and named as what it is. Cohort 1 carried about 91% of monarchE and drove the significant result; Cohort 2 is the thinner slice, and two years of abemaciclib carries a real diarrhea and venous thromboembolism burden she would be accepting on that thinner evidence, outside the labeled indication, with the insurance conversation that follows. I can defend prescribing it to her. I cannot defend telling her the label covers her, and I cannot defend ordering a test whose answer changes nothing.
Agreed: letrozole starts now, and no repeat Ki-67 is ordered — the group accepted that a second stain would re-measure a criterion the FDA stopped using in March 2023 and could not move her either way. Agreed too that if abemaciclib is offered, it is offered to her as an off-label recommendation resting on monarchE's Cohort 2, and named to her that way rather than described as standard adjuvant therapy.
Reads Cohort 2 as a genuine randomized result in a genuinely enrolled population, and would recommend abemaciclib to her on that basis, treating the label's silence as a regulatory simplification rather than a finding about her.
Reads the same cohort as the thinner 9% of the trial and is unwilling to recommend two years of added diarrhea and thromboembolic risk outside the indication; would present it as available rather than advised, and expects the coverage question to force the issue before she does.